Protective effects of ticlopidine and aspirin, administered alone and in combination, on thrombus formation in rat cerebral vessels.
The protective effects of ticlopidine and d,l-lysine acetylsalicylate (L-ASA), used alone and in combination, on the pathogenesis of thrombosis in cerebral blood vessels were investigated in a rat animal model using a He-Ne laser method. Ticlopidine and L-ASA, given orally at a concentration from 100 mg/kg, inhibited thrombus formation in a dose-dependent manner. Ticlopidine (300 mg/kg p.o.) inhibited thrombosis in arterioles and venules for 3 days after administration. The inhibitory activity of L-ASA (300 mg/kg p.o.) was less prolonged than that of ticlopidine and was observed for only approximately 24 h. Combined administration of ticlopidine and L-ASA significantly enhanced and prolonged the antithrombotic effects of either drug given alone. The results demonstrate that ticlopidine and L-ASA have potent antithrombotic properties in rat cerebral blood vessels in vivo.
Sasaki
Y
Y
Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Japan.
Ishii
I
I
Giddings
J C
JC
Yamamoto
J
J
D000818:Animals; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D002542:Intracranial Embolism and Thrombosis / Q000517:prevention & control*; D008239:Lysine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013988:Ticlopidine / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D008239:Lysine; D013988:Ticlopidine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate